<div id="readability-page-1"><p>Kennedy Capital Management LLC boosted its holdings in shares of  Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 380.2% in the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 27,955 shares of the company's stock after acquiring an additional 22,133 shares during the quarter. Kennedy Capital Management LLC owned 0.06% of Axsome Therapeutics worth $2,918,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Axsome Therapeutics</strong> alerts:</span></p></div><ul><li>5 medical stocks growing earnings by triple digits</li></ul><p>A number of other hedge funds have also added to or reduced their stakes in AXSM. Caitong International Asset Management Co. Ltd bought a new stake in  Axsome Therapeutics during the first quarter valued at about $25,000.  Quantbot Technologies LP acquired a new stake in shares of  Axsome Therapeutics during the first quarter worth about $31,000.  AlphaQuest LLC acquired a new stake in shares of  Axsome Therapeutics in the first quarter worth $38,000.  BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of  Axsome Therapeutics during the 1st quarter valued at about $47,000.  Finally, Ameritas Advisory Services LLC purchased a new position in  Axsome Therapeutics during the second quarter valued at approximately $77,000. 81.49% of the stock is currently owned by institutional investors. </p><h2>Insider Buying and Selling</h2><p>In related news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 10,558 shares of the firm's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44. Following the transaction, the chief executive officer directly owned 7,229 shares of the company's stock, valued at $1,071,193.22. The trade was a 59.36% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 407,959 shares of company stock worth $52,645,040. Insiders own  22.30% of the company's stock. </p><h2>Axsome Therapeutics Price Performance</h2><ul><li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li></ul><p>Shares of AXSM opened at $149.22 on Friday. The firm has a fifty day moving average price of $134.97 and a 200 day moving average price of $118.87. The stock has a market cap of $7.52 billion, a PE ratio of -31.95 and a beta of 0.48. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 1-year low of $75.56 and a 1-year high of $152.94. </p><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million for the quarter, compared to analysts' expectations of $162.96 million. Axsome Therapeutics's quarterly revenue was up 63.2% on a year-over-year basis.  As a group, sell-side analysts anticipate that  Axsome Therapeutics, Inc. will post -2.79 EPS for the current year. </p><h2>Analyst Ratings Changes</h2><ul><li>Why this is an Awesome Time to Buy Axsome Therapeutics</li></ul><p>Several equities analysts recently weighed in on the company. Needham &amp; Company LLC  restated a &#34;buy&#34; rating and issued a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 4th. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, November 4th. Mizuho lifted their price target on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 6th. Morgan Stanley upped their price objective on Axsome Therapeutics from $194.00 to $196.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, B. Riley started coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a &#34;buy&#34; rating and a $179.00 price target for the company. One equities research analyst  has rated the stock with a Strong Buy rating, sixteen have assigned  a Buy rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $179.88.</p><p><b>View Our Latest Report on Axsome Therapeutics</b></p><h2>About Axsome Therapeutics</h2> (Free Report)<p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p><h2>See Also</h2><ul><li>Five stocks we like better than Axsome Therapeutics</li><li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li><li>Best Aerospace Stocks Investing </li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>Dividend Capture Strategy: What You Need to Know</li><li>MarketBeat Week in Review – 12/1 - 12/5</li></ul><p><strong>Want to see what other hedge funds are holding AXSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AXSM

<p>Kennedy Capital Management LLC increased its holdings in Axsome Therapeutics, Inc. by 380.2% in Q2, owning 27,955 shares worth $2,918,000. Analysts have given positive ratings, with price targets ranging from $154 to $202, indicating potential growth. Insiders sold shares worth $52,645,040 in the last 90 days. Axsome's stock opened at $149.22, with a market cap of $7.52 billion.</p>

Kennedy Capital Management LLC Boosts Holdings in Axsome Therapeutics, Inc. $AXSM